Boston Scientific Corporation (NYSE:BSX) will release earnings for its fourth quarter before the opening bell on Wednesday, Feb. 4.Analysts expect the Marlborough, Massachusetts-based company to report quarterly earnings of 78 cents per share. That's up from 70 cents per share in the year-ago period. The consensus estimate for Boston Scientific's quarterly revenue is $5.28 billion (it reported $4.56 billion last year), according to Benzinga Pro.The U.S. Food and Drug Administration (FDA), last month, said i ...

Boston Scientific Corporation (NYSE:BSX) will release earnings for its fourth quarter before the opening bell on Wednesday, Feb. 4.Analysts expect the Marlborough, Massachusetts-based company to report quarterly earnings of 78 cents per share. That's up from 70 cents per share in the year-ago period. The consensus estimate for Boston Scientific's quarterly revenue is $5.28 billion (it reported $4.56 billion last year), according to Benzinga Pro.The U.S. Food and Drug Administration (FDA), last month, said i ...

传感器更小、佩戴更轻、算法更准，目标始终围绕 " 如何把一枚贴片戴得更久、更舒服"展开。 在连续血糖监测（CGM）领域，创新路径已经非常清晰： 但当佩戴式 CGM 的体验不断逼近极限，一个问题开始浮现： 如果真正的负担并不在"贴得好不好"，而在"是否需要反复贴"？ 01 从 FDA 到 CE：植入式 CGM 被"完整体系"接纳 2026年1月29日， Senseonics 宣布，其 Eversense 365 连续血糖监测系统 (CGM) 系统已 获得 CE 认证。 在此之前，该系统已于 2024 年 9 月获得 FDA 批准 ，成为 全球首个可在体内连续工作一整年的 CGM 。 随后，Senseonics 与其商业伙伴 Ascensia Diabetes Care 启动美国市场销售，并逐步接管该产品的全球商业化推进。 与多数 CGM 产品不同，Eversense 365 的监管难点并不在算法精度，而在 产品形态本身 ： 近期，一款 使用周期长达 365 天的植入式连续血糖监测系统 获得欧洲 CE 认证。这并不是对现有 CGM 路线的延长，而更像一次 对使用逻辑本身的重构 —— 把连续监测，从一种高频消耗的日 ...

Core Thesis - Penumbra, Inc. (PEN) is viewed positively due to its leading position in the thrombectomy market and strong operational fundamentals, despite recent stock price fluctuations driven by sector rotation [1][2][3][4]. Company Overview - Penumbra, Inc. specializes in thrombectomy and holds a near-monopoly position in the market, supported by proprietary catheter systems and software that enhance procedural precision [2]. - The company has a strong balance sheet with no debt, robust free cash flow, and improving margins, indicating operational excellence [4]. Stock Performance - PEN's stock has historically shown a predictable trading pattern, rallying into the low $300s and then selling off into the low $200s over the past five years [3]. - The recent stock pullback is attributed to broader sector rotation rather than any operational issues within PEN, positioning it attractively for future investment [3][4]. Future Outlook - Upcoming Q3 earnings are expected to be strong catalysts for the stock, with potential for a double-digit price movement if results exceed expectations [4]. - A price target of $300 is suggested as sentiment normalizes and fundamentals reassert themselves, reinforcing the bullish outlook on PEN [4]. Historical Context - The stock price has appreciated approximately 51.23% since a previous bullish thesis was published, indicating strong market confidence in the company's innovation and growth potential [5].

Core Viewpoint - Scott+Scott Attorneys at Law LLP has filed a class action lawsuit against Picard Medical Inc. and several associated defendants, alleging violations of the Securities Exchange Act due to misleading statements and a fraudulent stock promotion scheme that led to significant losses for investors [1][3]. Group 1: Lawsuit Details - The lawsuit is filed in the U.S. District Court for the Northern District of California under the case name Louie v. Picard Medical, Inc. et al., with a lead plaintiff deadline set for April 3, 2026 [1][5]. - The class action targets individuals and entities that purchased Picard Medical Securities (PMI) between September 2, 2025, and October 31, 2025, who suffered damages as a result [1][4]. Group 2: Allegations Against Defendants - The complaint alleges that the defendants made materially false and misleading statements and failed to disclose adverse facts about Picard Medical's business and operations [3]. - It is claimed that the defendants orchestrated a "pump-and-dump" scheme, where the stock price was artificially inflated through a social media promotion involving impersonators posing as legitimate financial advisors [2][3]. Group 3: Company Overview - Picard Medical is involved in the design, manufacturing, and sale of medical devices, with its flagship product being the artificial heart "SynCardia TAH" [2]. - The company is headquartered in Tucson, Arizona, and operates in the United States, Europe, and China [2].

As filed with the Securities and Exchange Commission on February 3, 2026. Registration No. 333-________ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 PROFUSA, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) Delaware 3841 86-3437271 (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Identification Number) 626 Bancroft Way ...

Group 1 - A class action lawsuit has been filed against Plug Power Inc. for allegedly misleading investors about its ability to receive and utilize a $1.66 billion loan from the U.S. Department of Energy (DOE) [1] - The lawsuit covers investors who purchased Plug Power securities between January 17, 2025, and November 13, 2025, and claims that the company overstated the likelihood of accessing the DOE loan funds [1] - Following the announcement of financial results on November 10, 2025, Plug Power's stock price fell by $0.09 per share, or 3.39%, closing at $2.53 per share [1] - On November 13, 2025, it was reported that Plug Power suspended its plans to construct six hydrogen production facilities, leading to a further decline in stock price by $0.48 per share, or 17.58%, closing at $2.25 per share [1] Group 2 - Robbins LLP is also involved in class action lawsuits for other companies, including Picard Medical, Inc. and Richtech Robotics Inc., indicating a broader trend of shareholder litigation in various sectors [2]

Core Viewpoint - Rosen Law Firm has announced a class action lawsuit against Picard Medical, Inc. for allegedly misleading investors regarding its business operations during the specified Class Period from September 2, 2025, to October 31, 2025 [1][2]. Allegations - The lawsuit claims that Picard Medical made materially false and misleading statements and failed to disclose significant adverse facts about its business and operations [3]. - Specific allegations include: 1. Involvement in a fraudulent stock promotion scheme utilizing social media misinformation and impersonation of financial professionals [3]. 2. Insiders and affiliates allegedly used offshore or nominee accounts to facilitate coordinated share dumping during a price inflation campaign [3]. 3. Public statements and risk disclosures from Picard omitted any mention of false rumors and artificial trading activity affecting stock prices [3]. 4. Positive statements made by the defendants regarding Picard's business and prospects were materially misleading and lacked a reasonable basis [3]. Participation in Class Action - Investors may be eligible to participate in the class action against Picard Medical, with a lead plaintiff representing other class members [4]. - Shareholders do not need to actively participate in the case to be eligible for recovery, and all representation is on a contingency fee basis, meaning no fees or expenses are incurred by shareholders [4]. About Rosen Law Firm - Rosen Law Firm is recognized for its active role in securities class actions and has successfully recovered over $1 billion for shareholders since its inception [5].

POMPANO BEACH, Fla., Feb. 03, 2026 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of perinatal tissue derived products for advanced wound care, today underscored the significance of recent remarks from U.S. Food and Drug Administration (FDA) leadership signaling openness to expanded use of Bayesian statistical methodologies in clinical trial design and analysis. FDA Commissioner, Dr. Martin Makary recentl ...

MINNEAPOLIS, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. (“Tactile Medical”; the “Company”) (Nasdaq: TCMD), a medical technology company providing therapies for people with chronic disorders, today announced that fourth quarter and fiscal year 2025 financial results will be released after the market closes on Tuesday, February 17, 2026. Management will host a conference call with a question and answer session at 5:00 p.m. Eastern Time on February 17, 2026, to discuss the results of th ...